✦ LIBER ✦

Efficacy and safety of intravenous voriconazole and intravenous itraconazole for antifungal prophylaxis in patients with acute myelogenous leukemia or high-risk myelodysplastic syndrome

✍ Scribed by Gloria N. Mattiuzzi; Jorge Cortes; Gladys Alvarado; Srdan Verstovsek; Charles Koller; Sherry Pierce; Deborah Blamble; Stefan Faderl; Lianchun Xiao; Mike Hernandez; Hagop Kantarjian

Publisher: Springer-Verlag
Year: 2009
Tongue: English
Weight: 139 KB
Volume: 19
Category: Article
ISSN: 0941-4355
DOI: 10.1007/s00520-009-0783-3

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Intravenous itraconazole for prophylaxis

Intravenous itraconazole for prophylaxis of systemic fungal infections in patients with acute myelogenous leukemia and high-risk myelodysplastic syndrome undergoing induction chemotherapy

✍ Gloria N. Mattiuzzi; Hagop Kantarjian; Susan O'Brien; Dimitrios P. Kontoyiannis; 📂 Article 📅 2004 🏛 John Wiley and Sons 🌐 English ⚖ 81 KB 👁 1 views

## Abstract ## BACKGROUND Systemic fungal infections remain the leading cause of mortality in patients with newly diagnosed acute myelogenous leukemia (AML) and high‐risk myelodysplastic syndrome (MDS). The objective of the current study was to determine whether intravenous itraconazole (I.V. ITRA

Predictors and outcome of acute kidney i

Predictors and outcome of acute kidney injury in patients with acute myelogenous leukemia or high-risk myelodysplastic syndrome

✍ Amit Lahoti; Hagop Kantarjian; Abdulla K. Salahudeen; Farhad Ravandi; Jorge E. C 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 185 KB 👁 1 views

Idarubicin, cytarabine, and topotecan in

Idarubicin, cytarabine, and topotecan in patients with refractory or relapsed acute myelogenous leukemia and high-risk myelodysplastic syndrome

✍ Seung Tae Lee; Joon Ho Jang; Hyung Chan Suh; Jee Sook Hahn; Yun Woong Ko; Yoo Ho 📂 Article 📅 2001 🏛 John Wiley and Sons 🌐 English ⚖ 97 KB 👁 2 views

Gemtuzumab, fludarabine, cytarabine, and

Gemtuzumab, fludarabine, cytarabine, and cyclosporine in patients with newly diagnosed acute myelogenous leukemia or high-risk myelodysplastic syndromes

✍ Apostolia Tsimberidou; Elihu Estey; Jorge Cortes; Deborah Thomas; Stefan Faderl; 📂 Article 📅 2003 🏛 John Wiley and Sons 🌐 English ⚖ 90 KB 👁 1 views

## Background: Gemtuzumab is used to treat patients with previously untreated or recurrent acute myelogenous leukemia (aml). the fludarabine and cytarabine (ara-c) regimen is active in these patients. resistance to gemtuzumab is associated with blast multidrug resistance (mdr). the objectives of th

Liposomal amphotericin B versus the comb

Liposomal amphotericin B versus the combination of fluconazole and itraconazole as prophylaxis for invasive fungal infections during induction : Chemotherapy for patients with acute myelogenous leukemia and myelodysplastic syndrome

✍ Gloria N. Mattiuzzi; Elihu Estey; Issam Raad; Francis Giles; Jorge Cortes; Yu Sh 📂 Article 📅 2003 🏛 John Wiley and Sons 🌐 English ⚖ 94 KB

## Abstract ## BACKGROUND Fungal infections are a major cause of morbidity and mortality in patients undergoing induction chemotherapy for acute myelogenous leukemia (AML) and myelodysplastic syndrome (MDS). The authors evaluated the efficacy and toxicity of liposomal amphotericin B (L‐AmB) compar

Results of imatinib mesylate therapy in

Results of imatinib mesylate therapy in patients with refractory or recurrent acute myeloid leukemia, high-risk myelodysplastic syndrome, and myeloproliferative disorders

✍ Jorge Cortes; Francis Giles; Susan O'Brien; Deborah Thomas; Maher Albitar; Mary 📂 Article 📅 2003 🏛 John Wiley and Sons 🌐 English ⚖ 92 KB 👁 2 views

## Abstract ## BACKGROUND Imatinib mesylate is a selective tyrosine kinase inhibitor of c‐abl, bcr/abl, c‐kit, and platelet‐derived growth factor‐receptor (PDGF‐R). c‐kit is expressed in most patients with acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) and PDGF has been implicated